

Safety and Efficacy of New Moroctocog Alfa Drug (Octofactor) in Prophylactic Treatment in Adolescent Patients with Severe and Moderate Hemophilia a

Ekaterina Shiller, Vladimir Vdovin, Victor Petrov, Pavel Svirin, Tatiana Andreeva, Inna Lavrichenko, Artem Bullikh, Igor Koltunov, Igor Davydkin, Igor Kurtov, Alexandr Shuster, Dmitry Kudlay, Sergey Lukyanov, Anton Borozinets, Eugene Nikitin, and Ekaterina Klykova

Blood 2015 126:4703:

[Article](#) [Info & Metrics](#)


Abstract

Efficacy and safety of a new domestically produced rFVIII-BDD (moroctocog alfa, Octofactor, CJSC "GENERIUM", Russia) was investigated in a controlled, open, prospective, multicenter clinical trial. After screening and a 4-days washout period 12 previously treated patients adolescents (age 12–18 years old) with severe hemophilia A (the activity of FVIII was less than 1%) were included in the clinical trial. The patients were given the moroctocog alfa as prophylactic treatment in a dose of 35±5 ME/kg 3 times per week during 21±1 weeks. Before participation in this clinical trial 2 pts had received treatment with another recombinant FVIII, 2 pts had therapy with pdFVIII and 8 pts had been treated with rFVIII and pdFVIII. The main criterion of drug efficacy was the incidence of spontaneous bleeding occurred within 48 hours after of the moroctocog alfa injection.

The additional criteria were:

- The severity of spontaneous bleeding occurred in 21 ± 1 week.
- Number of injections needed for the one episode of bleeding according of its severity.
- The total amount of drug administered over a period of prophylactic treatment and treatment "on demand".
- The number of patients with severe hemophilia A with a residual activity of FVIII ≥1% in 48 hours after the injection on prophylactic therapy.

During the follow up period (21±1 week) 17 bleeding episodes were registered, 2 of them (11,8%) were severe, 10 (58,8%) were moderate and 5 (29,4%) were mild (Tab.1). Number of bleeding episodes (spontaneous and traumatic) was 17 (1.55 in average). Number of spontaneous bleeding was 3 (17,6%), 1 of them was mild and 2 were moderate. The average number of injections that stop one bleeding episode was 1.7±0.8. The total amount of moroctocog alfa administered over a period was 1.502.000 IÅ for prophylactic treatment and 64.750 IÅ for "on demand" treatment. The number of patients with severe hemophilia A with a residual activity of FVIII ≥1% in 48 hours after injection on prophylactic therapy was 63,6% on visit 2, 90,09% on visit 3 and 81,1% on visit 4. The safety assessment was performed in 12 patients. There were 8 adverse events and 7 of them were not associated with drugs administration. There was one serious adverse effect, allergic reaction accompanied by arthralgia and cephalgia. The patient was excluded from the trial without consequences for life and health. There were no infection transmissions and de novo inhibitor incident. The study showed that moroctocog alfa is effective and safe in prophylactic treatment and stopping of bleeding in adolescents with severe hemophilia A.



[Download figure](#) | [Open in new tab](#) | [Download powerpoint](#)




Table 1. Efficacy evaluation [Download figure](#) | [Open in new tab](#) | [Download powerpoint](#)

Disclosures No relevant conflicts of interest to declare.

Take notes, share and follow articles, make comments, and collaborate with peers!
 DISCUSS
 ADD TO LIST
 FOLLOW
 SHARE
 COMMENT
 NOTE

- * Asterisk with author names denotes non-ASH members.

© 2015 by The American Society of Hematology

Potential Articles of Interest

US Economic Impact of Recombinant FVIII Vs Plasma-Derived FVIII/VWF in Previously Untreated Hemophilia a Patients
Robert F. Sidonio et al., Blood, 2017

Safety and Efficacy of New Nonacog Alfa Drug (Innonafactor) in Prophylactic Treatment in Patients with Severe and Moderate Hemophilia B
Maria Shamina et al., Blood, 2015

Prolonged bleeding-free period following prophylactic infusion of recombinant factor VIII reconstituted with pegylated liposomes.
Jack Spira et al., Blood, 2006

Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: Results from a 13-Month Crossover Study
Peter Collins et al., Blood, 2008

Safety and Efficacy of Turoctocog Alfa in Prevention and on-Demand Treatment of Bleeding Episodes in Patients with Hemophilia A
Dragana Janic et al., Blood, 2016

Evaluation of factor VIII polysialylation: Identification of a longer-acting experimental therapy in mice and monkeys
Helmut Glantschnig et al., J Pharmacol Exp Ther, 2019

Incorporation of Cu 3 BTC 2 nanocrystals to increase the permeability of polymeric membranes in O 2 /N 2 separation
Chong Yang Chuah et al., BMC Chemical Engineering, 2019

The Use of Oral Herbal Medicine (Hange-Shashin-To) in Patients with Pouchitis: A Pilot Study
Hiroki Matsuoka et al., Journal of the Anus, Rectum and Colon (JARC), 2018

Pharmacological Profile of JNJ-64179375: A Novel, Long Acting Exosite-1 Thrombin Inhibitor
Zheng Huang Devine et al., J Pharmacol Exp Ther, 2019

Patient characteristics associated with treatment response in patients receiving salivianolate injection for stable angina
Yana Qi et al., Journal of Evidence-Based Medicine, 2018

Powered by **TREND MD**



[Previous](#)

[Back to top](#)